Is Kiora Pharmaceuticals, Inc. overvalued or undervalued?

As of 9 May 2025, Kiora Pharmaceuticals, Inc. has moved from an attractive valuation grade to one that does not qualify. The company appears to be overvalued given its current financial metrics. Notably, the Price to Book Value stands at 0.40, while the EV to EBITDA is at 1.17. The Return on Capital Employed (ROCE) is exceptionally high at 1262.96%, but this is misleading as the company is loss-making, reflected in its negative P/E ratio and ROE of -44.68%.
In comparison to its peers, Kiora Pharmaceuticals has a valuation score of -0.8451, while SeqLL, Inc. is at -1.5744 and Hoth Therapeutics, Inc. at -1.7844, indicating that Kiora is relatively better positioned among its peers despite not qualifying for a positive valuation. The recent stock performance shows a decline of 15.86% over the past year, contrasting with a 10.26% gain in the S&P 500, reinforcing the notion that the stock is overvalued in the current market context.